Careful implementation of PCSK9 inhibitors in clinical practiceAug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)
CSI Rome Terje Pedersen (Oslo, Norway) defended the 'contra'-argument in a discussion on the use of PCSK9 inhibitors in current clinical practice. He explains to Lotte Koopal and Gijs Berkelmans (both UMC Utrecht, The Netherlands) that while being involved in clinical studies of a PCSK9 antibody, he is still comfortable in the contra-position.
- Prof. Pedersens affinity with and sceptic attitude towards PCSK9 inhibitors in clinical practice 0:06
- Is it ethical to wait with giving PCKS9-inhibiting treatment until the outcome data are known? 1:22
- Cost considerations of anti-PCSK9 therapy 2:09
- FOURIER study results are expected in spring 2017, including cost effectiveness data 3:12
- Expectations of the outcome data of the FOURIER trial 4:40
In the Cardiovascular Scene Investigation (CSI) series, young clinicians with an investigative mindset interview experts about the context and meaning of the results they just presented at the ESC congress.
The series is aimed to explore the background and practical implications of recent scientific developments, like those discussed in the session on PCSK9 inhibitors in the Gladiators Arena at the ESC Congress 2016, with speakers in this session.
Faculty & Disclosures
Terje Rolf Pedersen - Professor Emeritus - Department of Endocrinology, Morbid Obesity and Preventive Medicine, UiO Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway
Lotte Koopal and Gijs Berkelmans - UMC Utrecht, The Netherlands
The speakers did not receive financial compensation for participating in these interviews